The 41-kDa and 43-kDa mitogen-activated protein (MAP) kinases play a pivotal role in the mitogenic signal transduction pathway and are essential components of the MAP kinase cascade, which includes MAP kinase kinase (MEK) and Raf-1. As aberrant activation of signal transducing molecules such as Ras and Raf-1 has been linked with cancer, we examined whether constitutive activation of the 41-/43-kDa MAP kinases is associated with the neoplastic phenotype of 138 tumor cell lines and 102 primary tumors derived from various human organs. Constitutive activation of the MAP kinases was observed in 50 tumor cell lines (36.2%) in a rather tissue-speci®c manner: cell lines derived from pancreas, colon, lung, ovary and kidney showed especially high frequencies with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies with a limited degree of MAP kinase activation. We also detected constitutive activation of the 41-/43-kDa MAP kinases in a relatively large number of primary human tumors derived from kidney, colon and lung tissues but not from liver tissue. Many tumor cells, in which point mutations of ras genes were detected, showed constitutive activation of MAP kinases, however, there were also many exceptions to this observation. In contrast, the activation of the 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely associated with the activation of MEK and p90 rsk in all the tumor cells examined. These results suggest that the constitutive activation of 41-/43-kDa MAP kinases in tumor cells is not due to the disorder of MAP kinases themselves, but is due to the disorder of Raf-1, Ras, or some other signaling molecules upstream of Ras.
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Introduction
Posttranslational modi®cation of proteins by phosphorylation plays a central role in the regulation of many cellular events which include cell proliferation and dierentiation. This ubiquitous form of reversible covalent modi®cation of proteins is mediated by protein kinases, which are key components in a network of integrated signaling pathways (Cohen, 1992; Hunter, 1995; Pawson, 1995) .
The 41-and 43-kDa MAP kinases (ERK2 and ERK1, respectively) (Ray and Sturgill, 1987; Boulton et al., 1991) , which have originally been identi®ed as molecules whose tyrosine phosphorylation is commonly induced in cells treated with a variety of mitogenic agents (Cooper et al., 1984; Kohno, 1985) , are ubiquitous components of signal transduction pathways (Nishida and Gotoh, 1993; Cobb and Goldsmith, 1995; Seger and Krebs, 1995) . They are activated by phosphorylation on both threonine and tyrosine residues by dual speci®city kinases, MAP kinase/ERK kinase (MEK) 1 and 2. MEK activity is in turn regulated by serine phosphorylation catalyzed by MEK activators. The major MEK activator is a serine/threonine kinase, Raf-1. It has also been reported that the activated Ras-mediated translocation of Raf-1 to the plasma membrane is one of the necessary events for Raf-1 to be activated following phosphorylation (Avruch et al., 1994) . The identity of the kinase(s) that phosphorylate Raf-1, however, is poorly understood at present. The protein kinase cascade described above (the MAP kinase cascade) is activated in many cell types by diverse extracellular stimuli which elicit a wide array of physiological responses such as cell division, differentiation, and secretion (Nishida and Gotoh, 1993; Cobb and Goldsmith, 1995; Seger and Krebs, 1995) . The 41-and 43-kDa MAP kinases are serine/threonine kinases that phosphorylate and modulate the function of many proteins with substantial regulatory functions. These include other protein kinases (such as p90 rsk ), cytoskeletal proteins (such as microtuble-associated proteins), other enzymes (such as cytoplasmic phospholipase A 2 ), and transcription factors (such as Elk-1) (Davis, 1993) . Thus, the MAP kinases are thought to function as key intermediaries in intracellular signal transduction networks.
Aberrant expression and/or activation of signal transducing proteins have been linked with cancer. For example, overexpression of the epidermal growth factor receptor tyrosine kinase (c-erb B-1) gene (Yao et al., 1988) , loss of the amino-terminal regulatory domain to produce active c-Raf-1 kinase (Nakatsu et al., 1985) , and point mutations of the ras oncogenes to produce constitutively active Ras proteins (Shimizu et al., 1983; Barbacid, 1987; Bos, 1988) have been observed in several human cancers. In this respect, active mutants of MEK-1, made constitutive by deleting N-terminal amino acids 32 ± 52, as well as by changing regulatory phosphorylated serines (residues 218 and 222) to glutamic acid, have recently been shown to transform mammalian cells (Mansour et al., 1994; Cowley et al., 1994; Brunet et al., 1994) . However, few studies have examined disorders of the MAP kinase cascade in naturally occurring human tumors.
In this study, we have examined whether constitutive activation of the MAP kinase cascade is associated with the neoplastic phenotype of 138 cell lines derived from various human tumors. Constitutive activation of the 41-/43-kDa MAP kinases was observed in 50 tumor cell lines: cell lines derived from pancreas, colon, lung, ovary and kidney showed especially high frequencies of constitutive MAP kinase activation. We also detected constitutive activation of the MAP kinases in a large number of primary human tumors derived from colon, lung and kidney tissues but not from liver tissue.
Results

Constitutive activation of the 41-/43-kDa MAP kinases in human tumor cell lines
Activation of the 41-/43-kDa MAP kinases in tumor cells was examined by three dierent assay procedures: by measuring the appearance of their active forms which show reduced mobility in SDS ± PAGE due to phosphorylation of speci®c tyrosine and threonine residues (Chatani et al., 1992) , by measuring their tyrosine phosphorylation, and by performing a direct in vitro kinase assay of the immunoprecipitates using myelin basic protein (MBP) as the substrate. These analyses consistently gave essentially identical results ( Figure 1) . As the basal level of MAP kinase activity varied signi®cantly from cell line to cell line, we determined the kinase activity in each cell line under conditions of cell proliferation (exponentially growing phase), serum-starvation, and growth-stimulation (by the addition of 10% fetal bovine serum [FBS] to serum-starved cells for 10 min). In non-tumorous cells, signi®cant activation of the MAP kinases was observed only under serum-stimulated conditions: the MAP kinase activities of ®ve lines of human diploid ®broblasts (SF-TY, WI38, TIG-3. TIG-7 and skin ®broblasts) under proliferating conditions were between 8.8*19.1% (average=13.5+4.1%) of the levels observed under growth-stimulation conditions. Thus, tumor cells were considered to be positive (constitutive activation of the MAP kinases occurs) if, under proliferating conditions, their MAP kinase activity exceeded 20% of the level observed under growthstimulation conditions.
We did not detect signi®cant activation of the 41-/ 43-kDa MAP kinases in 26 out of the 138 cell lines analysed (18.8%), even when the cells were serumstarved for 48 h and then growth-stimulated for 10 min with 10% FBS or with a mixture of 20 ng/ml each of ), serum-starvation (SS; ), and growth-stimulation (GS;
). The MAP kinase assay was performed by incubating cell lysates (10 mg of protein) with anti-MAP kinase antibody followed by the kinase reaction as described under Materials and methods; radioactivity incorporated into MBP was determined. Each value represents the mean+S.D. of duplicate determinations of a representative experiment. Cell lysates (15 mg of protein) were resolved by SDS ± PAGE, blotted, probed by anti-MAP kinase antibody (aMAPK) or anti-phosphotyrosine antibody (aPY), followed by ECL detection. Closed arrowheads indicate positions of the phosphorylated (activated) forms of 41-kDa MAP kinase (pp41), while open arrowheads indicate positions of its unphosphorylated forms (p41). Data shown are representative of two to three separate experiments that gave essentially the same results. Tumor cells were classi®ed into four groups by comparing the level of MAP kinase activity under proliferating conditions with that under growth-stimulation conditions PDGF and EGF (data not shown): all these tumor cells apparently required FBS or PDGF/EGF for their growth. The proliferation of these cells appears to depend on a signaling pathway(s) which does not involve these MAP kinases; these tumor cells were classi®ed as`type 0'. In 62 tumor cell lines (44.9%), activation of the MAP kinases was observed under growth-stimulation conditions but not signi®cantly under proliferating conditions as in normal diploid ®broblasts; these tumor cells were classi®ed as`type I'. These two types of tumor cells (type 0 and type I) are those in which constitutive activation of the 41-/43-kDa MAP kinases was not detected. In contrast, constitutive activation of the MAP kinases was detected in 50 cell lines (36.2%). The degree of activation varied signi®cantly among the dierent cell lines: tumor cells whose MAP kinase activity under proliferating conditions exceeded 50% of the level of that under growth-stimulation conditions were classi®ed as`type III' (strong positive), and the rest as`type II'.
Representative results of such analyses on several tumor cell lines are shown in Figure 1 , and data on the 138 cell lines are summarized in Table 1 . Tumor cell lines derived from pancreas, colon, lung, ovary and kidney showed especially high frequencies of constitutive MAP kinase activation with a high degree of MAP kinase activation, while those derived from brain, esophagus, stomach, liver and of hematopoietic origin showed low frequencies of constitutive MAP kinase activation with only a limited degree of MAP kinase activation.
Constitutive activation of the 41-/43-kDa MAP kinases in human primary tumor tissues
We determined the activity of 41-/43-kDa MAP kinases in primary tumors of colon, lung, kidney and liver (adenocarcinomas of colon and lung, renal cell carcinomas, and hepatocellular carcinomas, respectively), which was compared with the activity in corresponding non-tumorous tissues derived from the same individual. It was rather dicult to categorize the constitutive activation of MAP kinases in some cases, because the activity appeared to be elevated not only in the tumor tissues but also in the non-tumorous tissues. This was particularly the case for tumors of the colon and lung (Figure 2 ). Many tumor cells have been reported to produce growth factors such as TGF-a and PDGF, which then stimulate the proliferation of tumor cells themselves (in an autocrine fashion) and also of the surrounding normal cells (in a paracrine fashion) (Sporn and Todaro, 1980) . Thus, the elevated MAP kinase activity observed in some non-tumorous tissues could be the result of such a paracrine stimulation of normal cells by growth factors produced by tumor cells. Alternatively, reactive changes such as inflammation and the immunoresponse may be at the basis of the increased MAP kinase activity of the non-tumorous tissues that surround tumors. In this study, MAP kinase was tentatively considered to be constitutively active when the activity in the tumor tissue samples was greater than (i) the average of that of the 102 nontumorous tissue samples ( 32 P-radioactivity incorporated into MBP was 4580+1240 c.p.m. in the standard assay condition employed; that of tumor tissue samples was 8750+2480 c.p.m.) and (ii) 1.5-fold of that in the matched non-tumorous tissue samples. Tumors in which MAP kinase activity exceeded the average of that of the non-tumorous tissue samples but was less than 1.5-fold of that in the matched non-tumorous tissue were considered to be false-positives of constitutive MAP kinase activation, and the others were classi®ed as negative.
Representative results of such analyses in several cases of lung and liver tissues are shown in Figure 2 , and data on 34 cases of colon tissues, 34 cases of lung tissues, 11 cases of kidney tissues, and 23 cases of liver tissues are summarized in Table 2 . In this context, we have previously shown that constitutive activation of the MAP kinases occurs in 12 out of 25 cases of human renal cell carcinoma (Oka et al., 1995) . Thus, in support of the results in established tumor cell lines, primary tumors derived from colon, lung and kidney showed high frequencies of constitutive MAP kinase activation, while liver tumors did not show signi®cant activation of the 41-/43-kDa MAP kinases.
Constitutive activation of the 41-/43-kDa MAP kinases is always associated with the constitutive activation of MEK Constitutive activation of the 41-/43-kDa MAP kinases in tumor cells can be induced through several mechanisms, which include the activation of 41-/43-kDa MAP kinases themselves, the activation of upstream signaling molecules such as MEK, Raf-1 and Ras (Nishida and Gotoh, 1993; Cobb and Goldsmith, 1995; Seger and Krebs, 1995) , and the inactivation of MAP kinase phosphatase (Sun et al., 1993; Ward et al., 1994) . In order to gain insight into the molecular mechanisms of constitutive activation of 41-/43-kDa MAP kinases, we ®rst examined the possible participation of a ras gene mutation. Many tumor cells, in which point mutations of ras genes were detected (Bos, 1988; Kawaguchi et al., 1997) , showed constitutive activation of MAP kinases. However, there were also many exceptions to this observation (Table  3 ). We then examined the possible association of the activation of Raf-1 kinase (an activator of MEK), MEK (the activator of MAP kinases) and p90 rsk (a substrate of MAP kinases) with the constitutive activation of 41-/43-kDa MAP kinases in tumor cells, by determining the activities of these kinases under conditions of cell proliferation, serum-starvation and growth-stimulation. To detect the activation of Raf-1 and p90 rsk , we examined their phosphorylation by monitoring the mobility sifts in SDS ± PAGE (activation of these kinases is reportedly accompanied by increased serine/threonine phosphorylation, which results in the decrease in their mobilities in SDS ± PAGE) (Daum et al., 1994; Sturgill et al., 1988) ; to detect the activation of MEK, we determined the GST-ERK2 K52R phosphorylation activity of anti-MEK1 antibody-immunoprecipitates in an in vitro kinase assay. The representative results of analyses of several tumor cells are shown in Figure 3 , and the data on 38 tumor cell lines are summarized in Table 4 (21 cell lines were positive for the constitutive activation of MAP kinases and 17 cell lines were negative). The activation of 41-/43-kDa MAP kinases was accompanied by the activation of Raf-1 in the majority of tumor cells and was completely associated with the activation of MEK and of p90 rsk in all the tumor cell lines examined. We also determined the activities of Raf-1 and p90 rsk by an in vitro kinase assay of the (Tanimura et al., 1998) , and obtained essentially the same results as those shown in Figure 3 (data not shown). Furthermore, the constitutive activation of MAP kinases was always associated with the constitutive activation of MEK in all the primary tumor samples analysed (Figure 2 ).
Discussion
In this study, we demonstrated that the constitutive activation of the 41-/43-kDa MAP kinases was observed in a relatively large number of human tumors. Analyses of established cell lines suggested that the constitutive activation of MAP kinases was induced in tumors in a rather tissue-speci®c manner; tumor cells derived from pancreas, colon, lung, ovary and kidney tissues showed especially high frequencies of MAP kinase activation, while those derived from brain, esophagus, stomach, liver tissues and hematopoietic cells showed low frequencies with only a limited degree of MAP kinase activation (Table 1) . Analyses of primary tumors obtained from patients with respective tumors at the time of surgical resection also gave similar results; tumors derived from colon, lung and kidney tissues showed high frequencies of MAP kinase activation, while tumors derived from liver tissue did not show any signi®cant activation of the 41-/43-kDa MAP kinases (Table 2) . Thus, although the MAP kinase cascade is an essential mitogenic signaling pathway in many types of cells (Nishida and Gotoh, 1993; Seger and Krebs, 1995) , inappropriate activation of the cascade may not be important for the carcinogenesis of several tissues such as liver, stomach and esophagus. Deregulation of other cytoplasmic signaling pathways (such as JAK/Stat pathway) and/ or inactivation of tumor suppressor proteins (such as Rb, p53, APC and p16
INK4a
) has also been linked with cancer. These abnormalities may contribute more to the carcinogenesis of tissues whose derived tumor cells show only a low incidence of MAP kinase activation. In accordance with this possibility, inactivation of p16
, for example, has been reported to occur with high frequency in various cancers including those of the esophagus and liver (Chaubert et al., 1997; Serrano, 1997) .
We have recently reported that constitutive activation of the 41-/43-kDa MAP kinases occurs in 12 out of 25 cases of human renal cell carcinomas, in which MAP kinase activation shows a signi®cant correlation with their histological grade (Oka et al., 1995) . This was also the case for the 11 cases of renal cell carcinomas analysed in this study (data not shown). The 41-/43-kDa MAP kinase activity in each of 138 human tumor cell lines was determined under conditions of cell proliferation, serum-starvation, or growth-stimulation: representative results of such analyses on several cell lines are shown in Figure 1 . Tumor cells were classi®ed into four groups by comparing the level of MAP kinase activity under proliferating conditions with that under growthstimulation conditions, as described in the text. Tumor cell lines with an asterisk are those in which the activation of Raf-1, MEK and p90 rsk was also examined (see Figure 3 and Table 4) In primary tumors derived from colon and lung tissues, such a positive correlation between MAP kinase activation and histological grade was not clearly observed. However, MAP kinase activation showed signi®cant correlation with the dierentiation grade of each of the tumor tissues from which the respective cell line was derived; ®ve of 21 cell lines derived from welldierentiated tumor tissues (seven, esophagus; three, stomach; ten, colon; one, ovary) showed constitutive activation of the MAP kinases, while 14 of 20 cell lines derived from poorly-dierentiated tumor tissues (four, esophagus; three, stomach; four, colon; ®ve, lung; four, ovary) showed constitutive MAP kinase activation. Taken together, these results suggest that constitutive activation of the MAP kinase signaling pathway may play a role in the carcinogenesis of human tumors. Activation of the 41-/43-kDa MAP kinases in tumor cells (established cell lines and primary tissues) was always associated with the activation of MEK, the activator of MAP kinases. Although constitutive activation of the MAP kinases can be induced through several mechanisms (Nishida and Gotoh, 1993; Cobb and Goldsmith, 1995; Seger and Krebs, 1995) , our results showing the co-activation of MEK and MAP kinases is all the tumor cells analysed suggest that the constitutive activation of 41-/43-kDa MAP kinases in these tumor cells is not due to the disorder of MAP kinases themselves. These results also suggest that inactivation of the MAP kinase phosphatases, which lie downstream of the MAP kinases and inactivate them Sun et al., 1993; Ward et al., 1994) , is not a cause of constitutive activation of 41-/43-kDa MAP kinases in tumor cells. These conclusions can be drawn from the fact that disorder of MAP kinases themselves or MAP kinase phosphatase induces the activation of 41-/43-kDa MAP kinases in the absence of the constitutive activation of MEK.
Rather, our results suggest that unregulated activation of some of the upstream signaling molecules such as MEK, Raf-1 or Ras play a causal role in the constitutive activation of 41-/43-kDa MAP kinases in tumor cells. With regard to this idea, it has recently 3 1 Figure 2 Activation of the 41-/43-kDa MAP kinases and MEK in human primary tumors derived from lung and liver tissues. Activities of the 41-/43-kDa MAP kinases and MEK in primary tumors of lung and liver (adenocarcinomas of the lung and hepatocellular carcinomas, respectively) (T) and in matched non-tumorous tissues (N) were determined. The MAP kinase assay (upper) and MEK assay (lower) was performed by incubating cell lysates (30 mg of protein for MAP kinase assay and 50 mg of protein for MEK assay) with respective antibodies followed by the kinase reaction. Radioactivity incorporated into MBP was determined by liquid scintillation spectrometer, and radioactivity incorporated into GST-ERK2 K52R was quanti®ed with a Fujix Bioimaging analyzer BAS 1500. Each value represents the mean+S.D. of duplicate determinations of a representative experiment. Cell lysates (30 mg of protein) were resolved by SDS ± PAGE, blotted, and probed with anti-MAP kinase antibody or anti-MEK1 antibody, followed by ECL detection. Closed arrowheads indicate positions of the phosphorylated (activated) forms of 41-and 43-kDa MAP kinases (pp41, pp43) and of the MEK (MEK), while open arrowheads indicate positions of the unphosphorylated forms of the MAP kinases. Data shown are representative of two to three separate experiments that gave essentially the same results been reported that mutations in the MEK genes are very rare in human lung cancer (Bansal et al., 1997) . Our results, showing the co-activation of MEK and Raf-1 (an activator of MEK) in almost all the tumor cells analysed (Table 3 ), suggest that mutational activation of MEK as the primary cause of constitutive activation of MAP kinases in tumor cells is possible but unlikely; which is consistent with the previous observation described above (Bansal et al., 1997) . The SF-539 glioblastoma cell line, which displays constitutive activation of MEK and MAP kinases without Raf-1 activation, is the only exception in our analysis. In this case, MEK might be activated through a Raf-1-independent pathway. Alternatively, a mutational alteration which induces the activation of MEK itself might have occurred; this possibility remains to be examined in future study. Our results also indicate that, when compared with that in matched normal tissues, the expression level of MEK protein in tumor tissues has a tendency to be increased regardless of whether or not MEK/MAP kinase activation is induced. This is in strong contrast to the fact that the amount of 41-/43-kDa MAP kinases is not signi®cantly dierent between tumor and normal tissues (Figure 2) . Although overexpression of MEK itself has been reported not to induce the activation of MAP kinases and cell transformation (Mansour et al., 1994; Cowley et al., 1994; Brunet et al., 1994) , the signi®cance and mechanistic basis of its overexpression require additional investigation.
Constitutive activation of the 41-/43-kDa MAP kinases in many tumor cells seems to be a consequence of the activation of Ras, because point mutations of ras genes have been observed in these cells. However, there are also many tumor cells which do not show abnormal activation of the MAP kinases, although point mutations of ras genes were detected (Table 2) . Alternatively, activation of the MAP kinases can be induced through Ras-independent The 41-/43-kDa MAP kinase activity in primary tumors of colon, lung, kidney and liver (adenocarcinomas of colon and lung, renal cell carcinomas, and hepatocellular carcinomas, respectively) was determined, which was compared with the activity in corresponding non-tumorous tissues derived from the same individual: representative results of such analyses on several cases are shown in Figure 2 . MAP kinase was considered to be constitutively active (+) when the activity in the tumor tissue was greater than the average of that of the 102 non-tumorous tissues and also greater than 1.5-fold of that in the matched non-tumorous tissue. Tumors, the MAP kinase activity of which exceeded the average of the non-tumorous tissue samples but was less than 1.5-fold of that in matched non-tumorous tissue samples, were classi®ed as false-positives of constitutive MAP kinase activation (+), and the others were classi®ed as negative (7) rsk was examined in each cell line under conditions of cell proliferation (CP), serum-starvation (SS) and growth-stimulation (GS) by monitoring the appearance of their more slowly migrating forms (phosphorylated forms; Raf-1-P, pp43/pp41 and p90 rsk -P). For the analyses, cell lysates (20 mg of protein) were resolved by SDS ± PAGE, blotted and probed with anti-Raf-1 antibody, anti-MAP kinase antibody or anti-p90 rsk antibody, followed by ECL detection. Activation of MEK was determined by incubating cell lysates (30 mg of protein) with anti-MEK1 antibody followed by the kinase reaction:
K52R is shown by autoradiography ( 32 P-ERK2). Data shown are representative of two to four separate experiments that gave essentially the same results pathways: no mutations have been detected in H-, K-, or N-ras genes in 12 cases of renal cell carcinomas, although constitutive activation of the MAP kinases has been clearly observed in these tumor cells (Oka et al., 1995) . Thus, although the precise cause of the constitutive activation of the MAP kinase signaling pathway is unclear in many tumor cells, it may be the result of a disorder of Raf-1 or some other signaling molecule upstream of Ras (such as receptor tyrosine kinases, GRB2, SOS, Shc, etc.) (Hunter, 1997) , which remains to be elucidated. In support of this idea, constitutive activation of the 41-/43-kDa MAP kinases is observed in A431 human vulval carcinoma cells which express a high level of EGF receptors; A431 cells are classi®ed as type II tumor cells with regard to the activation of the MAP kinases (data not shown).
Many tumor cell lines (26 out of the 138 cell lines analysed in this study) were found to possess novel characteristics with regard to the activation of their 41-/ 43-kDa MAP kinase signaling pathway; these`type 0' tumor cells did not show any signi®cant activation of Raf-1, MEK and 41-/43-kDa MAP kinases, even when they were serum-starved for 48 h and then growthstimulated for 10 min with 10% FBS or with a mixture of 20 ng/ml each of PDGF and EGF. Although all these tumor cells expressed Raf-1, MEK and 41-/43-kDa MAP kinases to similar degrees as those observed in other types of tumor cells (Figure 3) , their proliferation appeared not to depend on the activation of the MAP kinase pathway. We did not observe a signi®cant dierence between several growth characteristics (growth rate in monolayer culture, growth eciency in soft agar, etc.) of type 0, type I, type II or type III tumor cells (data not shown). The MAP kinase cascade is the major cytoplasmic kinase pathway activated by numerous mitogenic stimuli which interact with a diversity of structurally distinct receptors (Nishida and Gotoh, 1993; Cobb and Goldsmith, 1995; Seger and Krebs, 1995) , and it has also been shown that the activation of the pathway is necessary for the proliferation of ®broblasts (Mansour et al., 1994; Cowley et al., 1994; Brunet et al., 1994) . However, our present ®ndings suggest the existence of a novel mitogenic signaling pathway(s) which does not involve these well-characterized signaling molecules. The precise mechanism by which proliferation of the type 0 tumor cells is regulated remains to be determined.
In summary, we have demonstrated that constitutive activation of the MAP kinase signaling pathway is observed in a relatively large number of human tumors; tumor cells derived from pancreas, colon, lung, ovary and kidney tissues show especially high frequencies of MAP kinase activation. Our results also point to the possibility that speci®c inhibitors may be developed against signaling molecules such as MAP kinases and MEK for cancer therapy, and especially for the treatment of tumors in which constitutive activation of the 41-/43-kDa MAP kinases occurs.
Materials and methods
Materials
A polyclonal anti-MAP kinase antibody was raised against residues 299 ± 321 (RIEVEQALAHPYLEQYYDPSDEP) of 41-kDa MAP kinase (ERK2) and was shown to recognize both the 41-and 43-kDa MAP kinases (Chatani et al., 1992; Chatani et al., 1995) . The polyclonal anti-Raf-1 antibody (C-12) and polyclonal anti-p90 rsk antibody (C-21) were obtained from Santa Cruz Biotechnology, Inc. The monoclonal anti-MEK1 antibody was from Transduction Laboratories, and the monoclonal anti-phosphotyrosine antibody (4G10) were from Upstate Biotechnology, Inc. The cDNA for ERK2 K52R (Rossomando et al., 1992) was expressed in Escherichia coli as a GST-fusion protein, which was puri®ed by anity chromatography using GSHSepharose (Pharmacia Biotech Inc.) (Smith and Corcoran, 1990) . Other chemicals and reagents were of the purest grade available.
Cell lines and tissues
The human tumor cell lines examined in this study were purchased from the American Type Tissue Culture Collection, obtained through the Japanese Cancer Research Resources Bank, or described elsewhere (Shimada et al., 1992; Iwasaki et al., 1995; Kawaguchi et al., 1997; Kawada et al., 1998) . Each cell line was maintained under recommended and standard conditions; the majority of non-hematopoietic cells were cultured in Dulbecco's modi®ed Eagle's medium supplemented with 10% FBS, while the cells of hematopoietic origin were grown in RPMI 1640 medium supplemented with 10% FBS. For experimental use, subcon¯uent cell cultures in the respective growing medium were rendered quiescent by incubation for 48 h in serum-free medium (Dulbecco's modi®ed Eagle's medium or RPMI 1640 medium containing 2 mg/ml of bovine serum albumin [Boehringer Mannheim], 1 mg/ml of insulin [Sigma] , 2 mg/ml of transferrin [Sigma] , 30 Na 2 SeO 3 , and 10 mM HEPES, pH 7.4), and were then growth-stimulated with 10% FBS for 10 min. Samples of human primary tumors and normal tissues were obtained at the time of surgical resection under the permission of patients' Informed Consent; these samples were snap frozen in liquid nitrogen and stored at 7808C. , MEK and Raf-1 was determined in 38 tumor cell lines; these are those in Table 1 Cell lysis and immunoprecipitation Cells were washed twice with ice-cold phosphate-buered saline, scraped from plates into a hypotonic cell lysis buer (25 mM Tris-HCI, pH 7.4, 25 mM NaC1, 1 mM sodium orthovanadate, 10 mM NaF, 10 mM sodium pyrophosphate, 25 mM b-glycerophosphate, 25 mM p-nitrophenylphosphate, 20 nM okadaic acid, 0.2 mM sodium molybdate, 0.5 mM EGTA, 1 mM phenylmethylsulfonyl¯uoride, 10 mg/ml leupeptin, and 1% aprotinin), and then¯ash-frozen in liquid nitrogen. After three freeze-thaw cycles, cells were lysed by passing them through a 25-gauge needle followed by sonication for 60 s. Tissue samples were homogenized on ice in the hypotonic cell lysis buer, followed by sonication for 60 s. Lysates were cleared by centrifugation at 12 000 g for 30 min, and protein concentrations were determined using the BCA protein assay reagent (Pierce). Cell lysates (10*30 mg of protein) were then immunoprecipitated by incubating for 3 h at 48C with each of the respective antibodies preabsorbed to protein-A Sepharose (Pharmacia Biotech Inc.) (Iwasaki et al., 1996) . For protein kinase assays, immunoprecipitates were then washed twice with a kinase buer (50 mM Tris-HC1, pH 8.0, 25 mM MgC1 2 , 0.5 mM EGTA, 1 mM dithiothreitol, and 10% glycerol).
Protein kinase assays
41-/43-kDa MAP kinases and MEK activities were measured in an immune complex kinase assay as described previously (Iwasaki et al., 1996; Tanimura et al., 1998) . Brie¯y, each immunoprecipitate prepared as described above was incubated for 30*60 min at 308C with 20 mM ATP and 1*2 mCi of [g-32 P]ATP (Amersham) in 30 ml of the kinase buer: 41-/43-kDa MAP kinase assays were performed with 7.5 mg of MBP (Sigma) as a substrate, and MEK assays were performed using 2 mg of GST-ERK2 K52R . Radioactivity incorporated into MBP was determined by liquid scintillation spectrometry (for assays of 41-/43-kDa MAP kinases), or the incorporation of 32 P into GST-ERK2 K52R was examined by SDS ± PAGE followed by autoradiography using a Fujix Bioimaging analyzer BAS 1500 (Fujix Photo Film Co., Tokyo, Japan) (for assays of MEK). In each experiment we determined the activities of MAP kinases/MEK in the cell lysate (5 mg of protein) of Raf-1-transformed NIH3T3 cells (Li et al., 1993) ; these were used as internal standards in each experiment to normalize the activities of MAP kinases/MEK.
Western blot analysis
Cell lysates prepared as described above were separated by SDS ± PAGE, electrophoretically transferred onto an Immobilon-P membrane (Millipore), and probed with anti-Raf-1 antibody, anti-MEK1 antibody, anti-MAP kinase antibody, anti-p90 rsk antibody, or anti-phosphotyrosine antibody. Immunoreactive bands were then visualized by enhanced chemiluminescence (ECL) (Amersham) Iwasaki et al., 1996) .
